Compare VLY & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VLY | ERAS |
|---|---|---|
| Founded | 1927 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.8B | 6.3B |
| IPO Year | 1994 | 2021 |
| Metric | VLY | ERAS |
|---|---|---|
| Price | $14.14 | $14.34 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 9 |
| Target Price | $16.89 | ★ $24.11 |
| AVG Volume (30 Days) | ★ 6.8M | 4.9M |
| Earning Date | 10-22-2026 | 11-11-2026 |
| Dividend Yield | ★ 3.08% | N/A |
| EPS Growth | ★ 46.38 | 36.23 |
| EPS | ★ 0.57 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.61 | N/A |
| Revenue Next Year | $20.48 | N/A |
| P/E Ratio | $25.01 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.34 | $2.11 |
| 52 Week High | $15.20 | $24.28 |
| Indicator | VLY | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 66.03 | 44.01 |
| Support Level | $13.32 | $13.47 |
| Resistance Level | $15.00 | $15.03 |
| Average True Range (ATR) | 0.31 | 0.96 |
| MACD | 0.19 | 0.09 |
| Stochastic Oscillator | 88.26 | 43.75 |
Valley National Bancorp is a bank holding company that offers a full suite of national and regional banking solutions through various commercial, private banking, retail, insurance, and wealth management financial services products. It provides personalized service and customized solutions to assist its customers with their financial service needs. The group also offers niche financial services, including loan and deposit products for homeowners associations, cannabis-related business banking, and venture banking, which offers nationally. It manages its business operations under operating segments consisting of Consumer Banking; Commercial Banking; and Treasury and Corporate Other. The group generates the majority of its revenue from the Commercial Banking Segment.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.